The KRAS glycine-to-cysteine mutation (G12C) composes approximately 44% of KRAS mutations in non鈥搒mall cell lung cancer, with mutant KRas G12C present in approximately 13% of all patients with lung adenocarcinoma. Mutant KRas has been an oncogenic target for decades, but no viable ...
Brief Communication10 Jul 2020 Cancer Gene Therapy HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer Haitang Yang Shun-Qing Liang Ren-Wang Peng ArticleOpen Access20 Aug 2019 Oncogenesis Initiation of human mammary cell tumo...
Mutant KRAS (KM), the most common oncogene in lung cancer (LC), regulates fatty acid (FA) metabolism. However, the role of FA in LC tumorigenesis is still not sufficiently characterized. Here, we show that KMLC has a specific lipid profile, with high tri
The overall objective tumor response rate was 51%, indicating that AZD9291 was highly effective in patients with EGFR (T790M) mutant lung cancer whose disease had progressed during previous treatment with EGFR tyrosine kinase inhibitors [71, 72]. JBJ-04-125-02, as an EGFR-mutant allosteric ...
Bhattacharya S, Socinski M A, Burns T F. KRAS mutant lungcancer: progress thus far on an elusive therapeutic target[J/OL]. ClinTransl Med, 2015, 4(1): 35[2021-07-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678136/...
18. Jänne Pasi A, Shaw Alice T, Pereira José Rodrigues, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.[J] ...
1 Mutations in the KRAS gene are frequently found in different human cancers, such as cancer of the lung, large intestine, pancreas, and biliary tract.2 Almost 15% to 25% of patients with NSCLC have KRAS mutations, and more than 97% of KRAS-mutant cases affect exon 2 and 3 (G12, G...
Non-small cell lung cancer (NSCLC) patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation are associated with significant clinical heterogeneity and a poor prognosis to standard NSCLC therapies such as surgical resection, radiotherapy,
The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 y
showed that AMG 510 and MRTX849, respectively, inhibited phosphorylation of ERK and of the ribosomal protein S6 downstream of KRAS in two KRAS-G12C-mutant cancer cell lines (NCI-H358 NSCLC cells and MIA PaCa-2 PDAC cells). Both inhibitors also reduced cell viability, at least in part by...